Effects of Tanshinone IIA on the modulation of MIR-33a and the SREBP-2/Pcsk9 signaling pathway in hyperlipidemic rats

Molecular Medicine Reports

Volumn 13, Issue 6, 2016, Pages 4627-4635

  Jia, Lianqun ^a   Song, Nan ^a   Yang, Guanlin ^a   Ma, Yixin ^a   Li, Xuetao ^a   Lu, Ren ^a   Cao, Huimin ^a   Zhang, Ni ^a   Zhu, Meilin ^a   Wang, Junyan ^a   Leng, Xue ^a   Cao, Yuan ^a   Du, Ying ^a   Xu, Yue ^a  

^a LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Hyperlipidemia; MIR 33a; SREBP 2 Pcsk9; Tanshinone IIA

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 33A; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TANSHINONE IIA; UNCLASSIFIED DRUG; ABIETANE DERIVATIVE; MIRN33 MICRORNA, RAT; PCSK9 PROTEIN, RAT; PROPROTEIN CONVERTASE 9; TANSHINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL HYPERLIPIDEMIA; HISTOPATHOLOGY; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; MALE; METABOLIC REGULATION; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HYPERLIPIDEMIAS; LIVER; METABOLISM;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER 1; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 1; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; GENE EXPRESSION REGULATION; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICRORNAS; PROPROTEIN CONVERTASE 9; RATS; RECEPTORS, LDL; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 84966552441     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5133     Document Type: Article

References (46)

1. Chait A and Brunzell JD: Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am 19: 259-278, 1990.
2. Williams AD: Hyperlipidaemia and atherogenesis. Med Hypotheses 33: 213-217, 1990.
3. Xie Y, He YB, Zhang SX, Pan AQ, Zhang J, Guan XH, Wang JX and Guo WS: Treatment of combined hyperlipidemia patients by jiangzhi tongluo soft capsule combined atorvastatin calcium tablet: A clinical study. Chin J Int Trad Western Med 34: 1059-1063, 2014 (In Chinese).
4. Fruebis J, Bird DA, Pattison J and Palinski W: Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J Lipid Res 38: 2455-2464, 1997.
5. Tall AR, Yvan-Charvet L, Terasaaka N, Pagler T and Wang N: HDL, ABC transporters and cholesterol efflux: Implications for the treatment of atherosclerosis. Cell Metab 7: 365-375, 2008.
6. Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, Gao J, Chen S, Bao L, Huang H and Liu P: Tanshinone IIA attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol 46: 427-438, 2007.
7. Gao S, Liu Z, Li H, Little PJ, Liu P and Xu S: Cardiovascular actions and therapeutic potential of Tanshinone IIA. Atherosclerosis 220: 3-10, 2012.
8. Xu W, Yang J and Wu LM: Cardioprotective effects of anshinone IIA on myocardial ischemia injury in rats. Pharmazie 64: 332-336, 2009.
9. Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, Peng L and Zang YQ: The role of Tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antag-onism. Endocrinology 150: 104-113, 2009.
10. Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, Xu SW, Liu WH, Liu PQ and Huang HQ: Tanshinone IIA attenuates atherosclerosis in ApoE (-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 650: 275-884, 2011.
11. Jia LQ, Feng JY, Yang GL, Chen WN and Chen Y: Effect of Tanshinone IIA on TLR4 and TNF-α of endothelial cells induced by LPS. Chin J Cell Mol Immunol 27: 733-735, 2011 (In Chinese).
12. Jia LQ, Yang GL, Ren L, Chen WN, Feng JY, Gao Y, Zhang L, Li XT and Lei P: Tanshinone IIA reduces apoptosis induced by hydrogen peroxide in the human endothelium-derived EA.hy926 cells. J Ethnopharmacol 143: 100-108, 2012.
13. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, et al: MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (SREBP-2l) regulates HDL in vivo. Proc Natl Acad Sci USA 107: 17321-17326, 2010.
14. Dávalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, et al: MIR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 108: 9232-9237, 2011.
15. Wu CY, Tang ZH, Liu LS and Jiang ZS: Selecting pharmacological targets of Pcsk9. Chin J Biochem Mol Biol 25: 991-996, 2009 (In Chinese).
16. Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux AL, Grefhorst A, Staels B and Krempf M: Hepatic Pcsk9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 281: 6211-6218, 2006.
17. Attie AD: The mystery of Pcsk9. Arterioscler Thromb Vasc Biol 24: 1337-1339, 2004.
18. Steinberg D and Witztum JL: Inhibition of Pcsk9: A powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA 106: 9546-9547, 2009.
19. Dong B, Wu MH, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW and Liu J: Strong iduction of Pcsk9 gene expression through HNF1alpha and SREBP-2: Mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 51: 1486-1495, 2010.
20. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE and Näär AM: MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasi. Science 328: 1566-1569, 2010.
21. Attie AD: ABCA1: At the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 32: 172-179, 2007.
22. Fernández-Hernando C, Ramírez CM, Goedeke L and Suárez Y: MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Bio 33: 178-185, 2013.
23. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, Leclercq IA, MacDougald OA and Bommer GT: Expression of MIR-33 froman SREBP-2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 285: 33652-33661, 2010.
24. Fernández-Hernando C, Suárez Y, Rayner KJ and Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 22: 86-92, 2011.
25. Lewis GF and Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221-1232, 2005.
26. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, et al: Antagonism of MIR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 121: 2921-2931, 2011.
27. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, et al: Inhibition of MIR-33a/b in non-human primates raises plasma HDL and lowera VLDL triglycerides. Nature 478: 404-447, 2011.
28. Liu W, Zhai C, Zhang X, Zhang H, Jiang M, Zhou S, Liu Y, Zhao N and Zhao J: Research of the whole grain-soybean compound package to regulate the cholesterol metabolism by SREBP-2, LDLR and visfatin. J Hyg Res 42: 196-202, 2013 (In Chinese).
29. Xu W, Liu L and Homby D: c-IAP1 binds and processes Pcsk9 protein: Linking the c-IAP1 in a TNF-α pathway to Pcsk9-mediated LDLR degradation pathway. Molecules 17: 12086-12101, 2012.
30. Mani DN, Bawankule D and Saroj BK: Hyperlipidemic model: Studying lipid profile in small experimental animal. Int J Pharmacy Pharm Sci 4: 337-340, 2012.
31. Munshi RP, Joshi SG and Rane BN: Development of an experimental diet model in rats to study hyperlipidemia and insulin resistance, markers for coronary heart disease. Indian J Pharmacol 46: 270-246, 2014.
32. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, Isomoto H, Mizuta Y, Hayashida K, et al: Fatty liver in non-alcoholic non overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 17: 1098-1105, 2002.
33. Hilden M, Christoffersen P, Juhl E and Dalgaard JB: Liver histology in a 'normal' population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12: 593-597, 1997.
34. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ and Chen SY: Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: An epidemiological survey. World J Gastroenterol 9: 1106-1110, 2003.
35. Ikonen E: Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 9: 125-138, 2008.
36. Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, et al: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96: 3448-3456, 2011.
37. Brown MS and Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47, 1986.
38. Sharpe LJ and Brown AJ: Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun 373: 670-674, 2008.
39. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ and Fernández-Hernando C: MIR-33 contributes to the regulation of cholesterol homeostasis. Science 328: 1570-1573, 2010.
40. Maxwell KN and Breslow JL: Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 101: 7100-7105, 2004.
41. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al: Mutations in Pcsk9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156, 2003.
42. Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610, 2010.
43. Kato M, de Lencastre A, Pincus Z and Slack FJ: Dynamic expression of small non-coding RNAs, including novel microRNAs and piRNAs/21U-RNAs, during Caenorhabditis elegans development. Genome Biol 10: R54, 2009.
44. Roglans N, Peris C, Verd JC, Alegret M, Vázquez M, Sánchez RM and Laguna JC: Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats. Biochem Pharmacol 62: 803-809, 2011.
45. Horton JD and Shimomura I: Sterol regulatory element-binding proteins: Activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 10: 143-150, 1999.
46. Horton JD: Sterol regulatory element-binding proteins: Transcriptional activators of lipid synthesis. Biochem Soc Trans 30: 1091-1095, 2002.